NIPH Clinical Trials Search

Basic Information

Recruitment status
Health condition(s) or Problem(s) studied	Type 2 diabetes mellitus
Date of first enrollment	21/12/2011
Target sample size	136
Countries of recruitment
Study type	Interventional
Intervention(s)	investigational material(s) Generic name etc : LAF237 INN of investigational material : Vildagliptin Therapeutic category code : 396 Antidiabetic agents Dosage and Administration for Investigational material : Twice daily, oral control material(s) Generic name etc : Placebo INN of investigational material : Therapeutic category code : --- Other Dosage and Administration for Investigational material : Twice daily, oral

Outcome(s)

Primary Outcome	HbA1c
Secondary Outcome	HbA1c, Fasting plasma glucose, Safety

Key inclusion & exclusion criteria

Age minimum	>= 20age old
Age maximum	<= 74age old
Gender	Both
Include criteria	- Patients with type 2 diabetes inadequately controlled with diet, exercise and oral anti-diabetic therapy - HbA1c in the range of 7.0-10.0% - Body mass index in the range 20-35 kg/m2
Exclude criteria	- Type 1 diabetes, diabetes resulting from pancreatic injury, or secondary forms of diabetes - Significant heart diseases